Show simple item record

dc.contributor.advisorDouglas Lauffenburger and Roy Welsch.en_US
dc.contributor.authorWeinberg, Kerry Rachelen_US
dc.contributor.otherLeaders for Global Operations Program.en_US
dc.date.accessioned2016-09-13T19:24:35Z
dc.date.available2016-09-13T19:24:35Z
dc.date.copyright2016en_US
dc.date.issued2016en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/104314
dc.descriptionThesis: M.B.A., Massachusetts Institute of Technology, Sloan School of Management, 2016. In conjunction with the Leaders for Global Operations Program at MIT.en_US
dc.descriptionThesis: S.M. in Engineering Systems, Massachusetts Institute of Technology, Department of Biological Engineering, 2016. In conjunction with the Leaders for Global Operations Program at MIT.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (pages 71-75).en_US
dc.description.abstractBuilding biological understanding of the Chinese Hamster Ovary (CHO) system used to manufacture therapeutic proteins is paramount to efficient CHO bioprocess optimization. This understanding can be built by analyzing and synthesizing biological data; such as transcriptomic (gene expression), proteomic (protein levels), or metabolomic (metabolite levels). This thesis describes a streamlined workflow for analyzing transcriptomic data. This streamlined workflow not only reduced the barrier to conducting the analysis but also reduced the analysis cycle time. With the use of this workflow, a number of historical Amgen microarray datasets were mined to identify gene expression signatures indicative of productivity. The result of this mining identified key biological pathways specific to a highly productive Amgen cell line. This work suggests that these pathways are critical to heightened levels of protein production. Using this information to engineer future cell lines could enable Amgen to improve cellular protein production by over 30%, impacting costs associated with drug substance manufacturing. More broadly, this example of streamlining and standardizing transcriptomic data provides a framework for how Amgen Process Development can leverage biological data to improve CHO systems understanding and achieve operational impacts.en_US
dc.description.statementofresponsibilityby Kerry Rachel Weinberg.en_US
dc.format.extent75 pagesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsMIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.subjectBiological Engineering.en_US
dc.subjectLeaders for Global Operations Program.en_US
dc.titleStreamlining and standardizing transcriptomic analysis in Amgen process developmenten_US
dc.typeThesisen_US
dc.description.degreeM.B.A.en_US
dc.description.degreeS.M. in Engineering Systemsen_US
dc.contributor.departmentLeaders for Global Operations Program at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineering
dc.contributor.departmentSloan School of Management
dc.identifier.oclc958279112en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record